Stem Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a new patent application for the production of pluripotent stem cells from primordial germ cells.
Houston, TX (PRWEB) January 22, 2009 -- Stem Cell Innovations, Inc., (SCLL.PK) announced today that it has filed a new patent application for the production of pluripotent stem cells from primordial germ cells. "We have been working for several years to develop a more effective method for producing stem cells from germ cells," said CEO James H. Kelly, PhD. "This filing was submitted to secure our intellectual property prior to publication in the scientific literature."
The Company has been developing PluriCells™ for use in drug discovery. "This application builds on our already strong IP position in germ cell-derived stem cells and will allow us to expand in new directions," explained Kelly.
About Stem Cell Innovations, Inc.:
SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy.
Contact Stem Cell Innovations:
Dr. James H. Kelly, +1 281-679-7900
ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.
Forward Looking Statement
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
Copyright©2009 Vocus, Inc.
All rights reserved